Immutep Ltd (ASX:IMM) has dosed the first patient of its Phase 3 TACTI-004 non-small cell lung cancer trial – the final stage ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer ...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with efti will enrol approximately 756 patients at more than ...

Discover why Immutep's Eftilagimod Alpha shows promise in NSCLC and HNSCC trials, but cautious investment is advised. Explore more details here.

Immutep (IMMP) announces the first patient has been successfully dosed in the Company’s pivotal TACTI-004 Phase III trial. TACTI-004 will ...

In this article, we are going to take a look at where Immutep Limited (NASDAQ:IMMP) stands against other best ASX stocks to buy according to hedge funds. According to a report by the Australian ...

Sydney, Australia Friday, March 28, 2025, 18:00 Hrs [IST] ...

In the final episode of a six-part interview series on immunotherapy, Marc Voigt, CEO and Executive Director of Immutep ...

Immutep Limited announces a poster presentation on the TACTI-004 Phase III trial at the European Lung Cancer Congress 2025. Immutep Limited announced an upcoming poster presentation for its ...

Real time quote data is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

Explore Immutep stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for IMMP. Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer ...

SYDNEY, AUSTRALIA, March 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy ...